Provision of Stereotactic Radiosurgery / Radiotherapy (SRS /SRT) Services – (Intracranial) All Ages, All Indications including Paediatric Neuro-Oncology SRS/SRT Services

The objective of this procurement is to commission four Lots All Tiers Stereotactic Radiosurgery / Radiotherapy (SRS /SRT) Services – (Intracranial) all ages, including paediatric oncology services covering England. The eligibility criteria, lotting structure and scope of services are detailed in this document. Bidders must be located within the Lot geography for which they are bidding. Bidders are only required to deliver the Tier 1 and 2 services within the geographical catchment area served by the neurosurgical service in which they are based and not for the whole Lot geography.<br/>On completion of the procurement process, NHS England will complete a Market Engagement exercise scheduled, to follow the outcome from this procurement process for the remaining Tier 1 & Tier 2 services which will be open to all bidders.<br/>In order to be eligible, bidders must ensure that:<br/>a) The Service is delivered as part of an integrated neurosurgical and oncology service located within the same geographical area or city serving a population of at least 2 million in order to generate 100 SRS/SRT Tier 1&2 cases per year.<br/>b) The Service is delivered as part of an integrated paediatric neurosurgical and oncology service, commissioned to provide Paediatric Photon Radiotherapy located within the same geographical area or city to a Children’s Cancer Principal Treatment Centre (PTC)<br/>c) The neurosurgical centre must host the full range of specialist intracranial Multi-disciplinary Teams (MDT) for all clinical indications for adult and paediatric intracranial tumours, namely, combined Neurosciences Brain and Central Nervous System (CNS) MDT, and / or the individual neuro-oncology MDTs, skull base MDT, and pituitary MDT, neuro-vascular MDT and Paediatric oncology MDTs as listed in Table 1.2.<br/>d) The Service must deliver the complete range of SRS/SRT treatments including paediatric oncology indications (Table 1.2) and participate in the full range of specialist neurosurgical MDTs and generate a minimum annual activity volume of: (i) 100 SRS/SRT Tier 1 and Tier 2 cases; plus (ii) circa 200 Tier 3 and Tier 4 (combined) cases.<br/>SRS/SRT are methods of delivering doses of precisely targeted intracranial radiotherapy treatment and used for a wide range of malignant and benign intracranial conditions, as set-out within NHS England clinical commissioning policy. This comprises Tier 1-2 indications of cerebral metastases, non-skull base meningiomas, skull base tumours including Vestibular Schwannoma and meningioma, pituitary adenoma, and the Tier 3-4 indications including arteriovenous malformations, trigeminal neuralgia and paediatric CNS tumours. The prevalence of these conditions varies from less than one per 100,000 population to up to 30 per 100,000. <br/>This tiered service model is based on clinical indication prevalence and complexity and groups together more common, less complex conditions (called Tier 1&2) and less common and more complex conditions (called Tier 3&4).<br/>The two service specifications, cover: <br/>(i) Tier 1 & 2 indications for adults; and <br/>(ii) All tiers, all ages and all conditions as this better reflects service provision and pathways.<br/>This procurement is focused on the ALL Tiers, all ages Service Specification ONLY.<br/>The Lots will cover the whole of England based on the following Geographies:<br/>1. Lot 1: North England and North West England<br/>2. Lot 2: South Yorkshire and Midlands<br/>3. Lot 3: Greater London, East of England and South England<br/>4. Lot 4: South West of England. Additional information: Bidders will be required to adhere to the recommendations detailed in the NPSA report ‘Towards Safety in Radiotherapy’ and will be required to meet the Pre-Assessment Radiotherapy Quality Assurance Requirements by June 2024 at the latest.<br/>Bidders will be required to complete external Radiotherapy Quality Assurance (RTTQA) prior to contract award.<br/>On completion of the procurement process, NHS England will complete a Market Engagement exercise scheduled, to follow the outcome from this procurement process for the remaining Tier 1 & Tier 2 services which will be open to all bidders.<br/>The duration of this contract will be for a period of 5 years with the Commissioner having the option to extend the Contract for up to a further two years. Providers wishing to be considered for the delivery of these services will need to respond to the provider selection documentation and submit responses prior to the deadline stated in this notice. The ITT documentation including a questionnaire is available through the Atamis (Health Family) portal:<br/>https://health-family.force.com/s/Welcome<br/>(https://health-family.force.com/s/Welcome)<br/>The reference is C220364 and the closing date for completed ITT responses is 12:00pm, midday on Friday 23rd February 2024. There will also be an opportunity to attend a market engagement event via Microsoft Teams at 13:00pm on Thursday 25th January 2024. If you would like to participate in this event, please email:<br/>josselin.canevet@nhs.net<br/>by Wednesday 24th January 2024. All slides and questions and responses will be made available to all bidders following the event.

The objective of this procurement is to commission four Lots All Tiers Stereotactic Radiosurgery / Radiotherapy (SRS /SRT) Services – (Intracranial) all ages, including paediatric oncology services covering England. The eligibility criteria, lotting structure and scope of services are detailed in this document. Bidders must be located within the Lot geography for which they are bidding. Bidders are only required to deliver the Tier 1 and 2 services within the geographical catchment area served by the neurosurgical service in which they are based and not for the whole Lot geography.<br/>On completion of the procurement process, NHS England will complete a Market Engagement exercise scheduled, to follow the outcome from this procurement process for the remaining Tier 1 & Tier 2 services which will be open to all bidders.<br/>In order to be eligible, bidders must ensure that:<br/>a) The Service is delivered as part of an integrated neurosurgical and oncology service located within the same geographical area or city serving a population of at least 2 million in order to generate 100 SRS/SRT Tier 1&2 cases per year.<br/>b) The Service is delivered as part of an integrated paediatric neurosurgical and oncology service, commissioned to provide Paediatric Photon Radiotherapy located within the same geographical area or city to a Children’s Cancer Principal Treatment Centre (PTC)<br/>c) The neurosurgical centre must host the full range of specialist intracranial Multi-disciplinary Teams (MDT) for all clinical indications for adult and paediatric intracranial tumours, namely, combined Neurosciences Brain and Central Nervous System (CNS) MDT, and / or the individual neuro-oncology MDTs, skull base MDT, and pituitary MDT, neuro-vascular MDT and Paediatric oncology MDTs as listed in Table 1.2.<br/>d) The Service must deliver the complete range of SRS/SRT treatments including paediatric oncology indications (Table 1.2) and participate in the full range of specialist neurosurgical MDTs and generate a minimum annual activity volume of: (i) 100 SRS/SRT Tier 1 and Tier 2 cases; plus (ii) circa 200 Tier 3 and Tier 4 (combined) cases.<br/>SRS/SRT are methods of delivering doses of precisely targeted intracranial radiotherapy treatment and used for a wide range of malignant and benign intracranial conditions, as set-out within NHS England clinical commissioning policy. This comprises Tier 1-2 indications of cerebral metastases, non-skull base meningiomas, skull base tumours including Vestibular Schwannoma and meningioma, pituitary adenoma, and the Tier 3-4 indications including arteriovenous malformations, trigeminal neuralgia and paediatric CNS tumours. The prevalence of these conditions varies from less than one per 100,000 population to up to 30 per 100,000. <br/>This tiered service model is based on clinical indication prevalence and complexity and groups together more common, less complex conditions (called Tier 1&2) and less common and more complex conditions (called Tier 3&4).<br/>The two service specifications, cover: <br/>(i) Tier 1 & 2 indications for adults; and <br/>(ii) All tiers, all ages and all conditions as this better reflects service provision and pathways.<br/>This procurement is focused on the ALL Tiers, all ages Service Specification ONLY.<br/>The Lots will cover the whole of England based on the following Geographies:<br/>1. Lot 1: North England and North West England<br/>2. Lot 2: South Yorkshire and Midlands<br/>3. Lot 3: Greater London, East of England and South England<br/>4. Lot 4: South West of England. Additional information: Bidders will be required to adhere to the recommendations detailed in the NPSA report ‘Towards Safety in Radiotherapy’ and will be required to meet the Pre-Assessment Radiotherapy Quality Assurance Requirements by June 2024 at the latest.<br/>Bidders will be required to complete external Radiotherapy Quality Assurance (RTTQA) prior to contract award.<br/>On completion of the procurement process, NHS England will complete a Market Engagement exercise scheduled, to follow the outcome from this procurement process for the remaining Tier 1 & Tier 2 services which will be open to all bidders.<br/>The duration of this contract will be for a period of 5 years with the Commissioner having the option to extend the Contract for up to a further two years. Providers wishing to be considered for the delivery of these services will need to respond to the provider selection documentation and submit responses prior to the deadline stated in this notice. The ITT documentation including a questionnaire is available through the Atamis (Health Family) portal:<br/>https://health-family.force.com/s/Welcome<br/>(https://health-family.force.com/s/Welcome)<br/>The reference is C220364 and the closing date for completed ITT responses is 12:00pm, midday on Friday 23rd February 2024. There will also be an opportunity to attend a market engagement event via Microsoft Teams at 13:00pm on Thursday25th January 2024. If you would like to participate in this event, please email:<br/>josselin.canevet@nhs.net<br/>by Wednesday 24th January 2024. All slides and questions and responses will be made available to all bidders following the event.

The objective of this procurement is to commission four Lots All Tiers Stereotactic Radiosurgery / Radiotherapy (SRS /SRT) Services – (Intracranial) all ages, including paediatric oncology services covering England. The eligibility criteria, lotting structure and scope of services are detailed in this document. Bidders must be located within the Lot geography for which they are bidding. Bidders are only required to deliver the Tier 1 and 2 services within the geographical catchment area served by the neurosurgical service in which they are based and not for the whole Lot geography.<br/>On completion of the procurement process, NHS England will complete a Market Engagement exercise scheduled, to follow the outcome from this procurement process for the remaining Tier 1 & Tier 2 services which will be open to all bidders.<br/>In order to be eligible, bidders must ensure that:<br/>a) The Service is delivered as part of an integrated neurosurgical and oncology service located within the same geographical area or city serving a population of at least 2 million in order to generate 100 SRS/SRT Tier 1&2 cases per year.<br/>b) The Service is delivered as part of an integrated paediatric neurosurgical and oncology service, commissioned to provide Paediatric Photon Radiotherapy located within the same geographical area or city to a Children’s Cancer Principal Treatment Centre (PTC)<br/>c) The neurosurgical centre must host the full range of specialist intracranial Multi-disciplinary Teams (MDT) for all clinical indications for adult and paediatric intracranial tumours, namely, combined Neurosciences Brain and Central Nervous System (CNS) MDT, and / or the individual neuro-oncology MDTs, skull base MDT, and pituitary MDT, neuro-vascular MDT and Paediatric oncology MDTs as listed in Table 1.2.<br/>d) The Service must deliver the complete range of SRS/SRT treatments including paediatric oncology indications (Table 1.2) and participate in the full range of specialist neurosurgical MDTs and generate a minimum annual activity volume of: (i) 100 SRS/SRT Tier 1 and Tier 2 cases; plus (ii) circa 200 Tier 3 and Tier 4 (combined) cases.<br/>SRS/SRT are methods of delivering doses of precisely targeted intracranial radiotherapy treatment and used for a wide range of malignant and benign intracranial conditions, as set-out within NHS England clinical commissioning policy. This comprises Tier 1-2 indications of cerebral metastases, non-skull base meningiomas, skull base tumours including Vestibular Schwannoma and meningioma, pituitary adenoma, and the Tier 3-4 indications including arteriovenous malformations, trigeminal neuralgia and paediatric CNS tumours. The prevalence of these conditions varies from less than one per 100,000 population to up to 30 per 100,000. <br/>This tiered service model is based on clinical indication prevalence and complexity and groups together more common, less complex conditions (called Tier 1&2) and less common and more complex conditions (called Tier 3&4).<br/>The two service specifications, cover: <br/>(i) Tier 1 & 2 indications for adults; and <br/>(ii) All tiers, all ages and all conditions as this better reflects service provision and pathways.<br/>This procurement is focused on the ALL Tiers, all ages Service Specification ONLY.<br/>The Lots will cover the whole of England based on the following Geographies:<br/>1. Lot 1: North England and North West England<br/>2. Lot 2: South Yorkshire and Midlands<br/>3. Lot 3: Greater London, East of England and South England<br/>4. Lot 4: South West of England. Additional information: Bidders will be required to adhere to the recommendations detailed in the NPSA report ‘Towards Safety in Radiotherapy’ and will be required to meet the Pre-Assessment Radiotherapy Quality Assurance Requirements by June 2024 at the latest.<br/>Bidders will be required to complete external Radiotherapy Quality Assurance (RTTQA) prior to contract award.<br/>On completion of the procurement process, NHS England will complete a Market Engagement exercise scheduled, to follow the outcome from this procurement process for the remaining Tier 1 & Tier 2 services which will be open to all bidders.<br/>The duration of this contract will be for a period of 5 years with the Commissioner having the option to extend the Contract for up to a further two years. Providers wishing to be considered for the delivery of these services will need to respond to the provider selection documentation and submit responses prior to the deadline stated in this notice. The ITT documentation including a questionnaire is available through the Atamis (Health Family) portal:<br/>https://health-family.force.com/s/Welcome<br/>(https://health-family.force.com/s/Welcome)<br/>The reference is C220364 and the closing date for completed ITT responses is 12:00pm, midday on Friday 23rd February 2024. There will also be an opportunity to attend a market engagement event via Microsoft Teams at 13:00pm on Thursday 25th January 2024. If you would like to participate in this event, please email:<br/>josselin.canevet@nhs.net<br/>by Wednesday 24th January 2024. All slides and questions and responses will be made available to all bidders following the event.

The objective of this procurement is to commission four Lots All Tiers Stereotactic Radiosurgery / Radiotherapy (SRS /SRT) Services – (Intracranial) all ages, including paediatric oncology services covering England. The eligibility criteria, lotting structure and scope of services are detailed in this document. Bidders must be located within the Lot geography for which they are bidding. Bidders are only required to deliver the Tier 1 and 2 services within the geographical catchment area served by the neurosurgical service in which they are based and not for the whole Lot geography.<br/>On completion of the procurement process, NHS England will complete a Market Engagement exercise scheduled, to follow the outcome from this procurement process for the remaining Tier 1 & Tier 2 services which will be open to all bidders.<br/>In order to be eligible, bidders must ensure that:<br/>a) The Service is delivered as part of an integrated neurosurgical and oncology service located within the same geographical area or city serving a population of at least 2 million in order to generate 100 SRS/SRT Tier 1&2 cases per year.<br/>b) The Service is delivered as part of an integrated paediatric neurosurgical and oncology service, commissioned to provide Paediatric Photon Radiotherapy located within the same geographical area or city to a Children’s Cancer Principal Treatment Centre (PTC)<br/>c) The neurosurgical centre must host the full range of specialist intracranial Multi-disciplinary Teams (MDT) for all clinical indications for adult and paediatric intracranial tumours, namely, combined Neurosciences Brain and Central Nervous System (CNS) MDT, and / or the individual neuro-oncology MDTs, skull base MDT, and pituitary MDT, neuro-vascular MDT and Paediatric oncology MDTs as listed in Table 1.2.<br/>d) The Service must deliver the complete range of SRS/SRT treatments including paediatric oncology indications (Table 1.2) and participate in the full range of specialist neurosurgical MDTs and generate a minimum annual activity volume of: (i) 100 SRS/SRT Tier 1 and Tier 2 cases; plus (ii) circa 200 Tier 3 and Tier 4 (combined) cases.<br/>SRS/SRT are methods of delivering doses of precisely targeted intracranial radiotherapy treatment and used for a wide range of malignant and benign intracranial conditions, as set-out within NHS England clinical commissioning policy. This comprises Tier 1-2 indications of cerebral metastases, non-skull base meningiomas, skull base tumours including Vestibular Schwannoma and meningioma, pituitary adenoma, and the Tier 3-4 indications including arteriovenous malformations, trigeminal neuralgia and paediatric CNS tumours. The prevalence of these conditions varies from less than one per 100,000 population to up to 30 per 100,000. <br/>This tiered service model is based on clinical indication prevalence and complexity and groups together more common, less complex conditions (called Tier 1&2) and less common and more complex conditions (called Tier 3&4).<br/>The two service specifications, cover: <br/>(i) Tier 1 & 2 indications for adults; and <br/>(ii) All tiers, all ages and all conditions as this better reflects service provision and pathways.<br/>This procurement is focused on the ALL Tiers, all ages Service Specification ONLY.<br/>The Lots will cover the whole of England based on the following Geographies:<br/>1. Lot 1: North England and North West England<br/>2. Lot 2: South Yorkshire and Midlands<br/>3. Lot 3: Greater London, East of England and South England<br/>4. Lot 4: South West of England. Additional information: Bidders will be required to adhere to the recommendations detailed in the NPSA report ‘Towards Safety in Radiotherapy’ and will be required to meet the Pre-Assessment Radiotherapy Quality Assurance Requirements by June 2024 at the latest.<br/>Bidders will be required to complete external Radiotherapy Quality Assurance (RTTQA) prior to contract award.<br/>On completion of the procurement process, NHS England will complete a Market Engagement exercise scheduled, to follow the outcome from this procurement process for the remaining Tier 1 & Tier 2 services which will be open to all bidders.<br/>The duration of this contract will be for a period of 5 years with the Commissioner having the option to extend the Contract for up to a further two years. Providers wishing to be considered for the delivery of these services will need to respond to the provider selection documentation and submit responses prior to the deadline stated in this notice. The ITT documentation including a questionnaire is available through the Atamis (Health Family) portal:<br/>https://health-family.force.com/s/Welcome<br/>(https://health-family.force.com/s/Welcome)<br/>The reference is C220364 and the closing date for completed ITT responses is 12:00pm, midday on Friday 9th 23rd February 2024. There will also be an opportunity to attend a market engagement event via Microsoft Teams at 13:00pm on Thursday 25th January 2024. If you would like to participate in this event, please email:<br/>josselin.canevet@nhs.net<br/>by Wednesday 24th January 2024. All slides and questions and responses will be made available to all bidders following the event.